Long-term effectiveness and safety of varenicline and nicotine replacement therapy in people with neurodevelopmental disorders: A prospective cohort study

Taha Itani, Dheeraj Rai, Tim Jones, Gemma Taylor, Kyla H Thomas, Richard Martin, Marcus R Munafò, Neil Davies, Amy Taylor

Research output: Contribution to journalArticle

Abstract

This study aimed to determine the effectiveness and safety of varenicline versus NRT for smoking cessation in people with neurodevelopmental disorders, compared to those without, at up to four years after exposure. We analysed electronic medical records from the Clinical Practice Research Datalink using three different statistical approaches: multivariable logistic regression, propensity score matching (PSM), and instrumental variable analysis. Exposure was prescription of varenicline versus NRT and the primary outcome was smoking cessation at 2-years. We included 235,314 people aged 18 and above with eligible smoking cessation prescriptions in the effectiveness analysis. Smokers with neurodevelopmental disorders were 48% less likely (95% confidence interval: 42%, 54%) to be prescribed varenicline than NRT, compared to smokers without neurodevelopmental disorders. At 2-year follow-up, smokers with neurodevelopmental disorders prescribed varenicline were 38% more likely to quit smoking (95% confidence interval: 6%, 78%). Similar results were obtained using PSM and instrumental variable analyses. There was little evidence showing that varenicline increased the likelihood of mental health related adverse events in people with neurodevelopmental disorders. Varenicline is less likely to be prescribed to people with neurodevelopmental disorders despite results suggesting it is more effective than NRT and little evidence of increased likelihood of mental health related adverse events.
Original languageEnglish
Article number19488
JournalScientific Reports
Volume9
Issue number1
DOIs
Publication statusPublished - 20 Dec 2019

Keywords

  • CPRD
  • Varenicline
  • NRT
  • Smoking Cessation
  • Neurodevelopmental Disorders
  • Primary Care
  • instrumental variable analyses

Cite this

Long-term effectiveness and safety of varenicline and nicotine replacement therapy in people with neurodevelopmental disorders: A prospective cohort study. / Itani, Taha; Rai, Dheeraj ; Jones, Tim ; Taylor, Gemma; Thomas, Kyla H; Martin, Richard; Munafò, Marcus R; Davies, Neil; Taylor, Amy.

In: Scientific Reports, Vol. 9, No. 1, 19488, 20.12.2019.

Research output: Contribution to journalArticle

Itani, Taha ; Rai, Dheeraj ; Jones, Tim ; Taylor, Gemma ; Thomas, Kyla H ; Martin, Richard ; Munafò, Marcus R ; Davies, Neil ; Taylor, Amy. / Long-term effectiveness and safety of varenicline and nicotine replacement therapy in people with neurodevelopmental disorders: A prospective cohort study. In: Scientific Reports. 2019 ; Vol. 9, No. 1.
@article{a92aa1068b7c4f10b99cf173105ef53e,
title = "Long-term effectiveness and safety of varenicline and nicotine replacement therapy in people with neurodevelopmental disorders: A prospective cohort study",
abstract = "This study aimed to determine the effectiveness and safety of varenicline versus NRT for smoking cessation in people with neurodevelopmental disorders, compared to those without, at up to four years after exposure. We analysed electronic medical records from the Clinical Practice Research Datalink using three different statistical approaches: multivariable logistic regression, propensity score matching (PSM), and instrumental variable analysis. Exposure was prescription of varenicline versus NRT and the primary outcome was smoking cessation at 2-years. We included 235,314 people aged 18 and above with eligible smoking cessation prescriptions in the effectiveness analysis. Smokers with neurodevelopmental disorders were 48{\%} less likely (95{\%} confidence interval: 42{\%}, 54{\%}) to be prescribed varenicline than NRT, compared to smokers without neurodevelopmental disorders. At 2-year follow-up, smokers with neurodevelopmental disorders prescribed varenicline were 38{\%} more likely to quit smoking (95{\%} confidence interval: 6{\%}, 78{\%}). Similar results were obtained using PSM and instrumental variable analyses. There was little evidence showing that varenicline increased the likelihood of mental health related adverse events in people with neurodevelopmental disorders. Varenicline is less likely to be prescribed to people with neurodevelopmental disorders despite results suggesting it is more effective than NRT and little evidence of increased likelihood of mental health related adverse events.",
keywords = "CPRD, Varenicline, NRT, Smoking Cessation, Neurodevelopmental Disorders, Primary Care, instrumental variable analyses",
author = "Taha Itani and Dheeraj Rai and Tim Jones and Gemma Taylor and Thomas, {Kyla H} and Richard Martin and Munaf{\`o}, {Marcus R} and Neil Davies and Amy Taylor",
year = "2019",
month = "12",
day = "20",
doi = "10.1038/s41598-019-54727-5",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Research",
number = "1",

}

TY - JOUR

T1 - Long-term effectiveness and safety of varenicline and nicotine replacement therapy in people with neurodevelopmental disorders: A prospective cohort study

AU - Itani, Taha

AU - Rai, Dheeraj

AU - Jones, Tim

AU - Taylor, Gemma

AU - Thomas, Kyla H

AU - Martin, Richard

AU - Munafò, Marcus R

AU - Davies, Neil

AU - Taylor, Amy

PY - 2019/12/20

Y1 - 2019/12/20

N2 - This study aimed to determine the effectiveness and safety of varenicline versus NRT for smoking cessation in people with neurodevelopmental disorders, compared to those without, at up to four years after exposure. We analysed electronic medical records from the Clinical Practice Research Datalink using three different statistical approaches: multivariable logistic regression, propensity score matching (PSM), and instrumental variable analysis. Exposure was prescription of varenicline versus NRT and the primary outcome was smoking cessation at 2-years. We included 235,314 people aged 18 and above with eligible smoking cessation prescriptions in the effectiveness analysis. Smokers with neurodevelopmental disorders were 48% less likely (95% confidence interval: 42%, 54%) to be prescribed varenicline than NRT, compared to smokers without neurodevelopmental disorders. At 2-year follow-up, smokers with neurodevelopmental disorders prescribed varenicline were 38% more likely to quit smoking (95% confidence interval: 6%, 78%). Similar results were obtained using PSM and instrumental variable analyses. There was little evidence showing that varenicline increased the likelihood of mental health related adverse events in people with neurodevelopmental disorders. Varenicline is less likely to be prescribed to people with neurodevelopmental disorders despite results suggesting it is more effective than NRT and little evidence of increased likelihood of mental health related adverse events.

AB - This study aimed to determine the effectiveness and safety of varenicline versus NRT for smoking cessation in people with neurodevelopmental disorders, compared to those without, at up to four years after exposure. We analysed electronic medical records from the Clinical Practice Research Datalink using three different statistical approaches: multivariable logistic regression, propensity score matching (PSM), and instrumental variable analysis. Exposure was prescription of varenicline versus NRT and the primary outcome was smoking cessation at 2-years. We included 235,314 people aged 18 and above with eligible smoking cessation prescriptions in the effectiveness analysis. Smokers with neurodevelopmental disorders were 48% less likely (95% confidence interval: 42%, 54%) to be prescribed varenicline than NRT, compared to smokers without neurodevelopmental disorders. At 2-year follow-up, smokers with neurodevelopmental disorders prescribed varenicline were 38% more likely to quit smoking (95% confidence interval: 6%, 78%). Similar results were obtained using PSM and instrumental variable analyses. There was little evidence showing that varenicline increased the likelihood of mental health related adverse events in people with neurodevelopmental disorders. Varenicline is less likely to be prescribed to people with neurodevelopmental disorders despite results suggesting it is more effective than NRT and little evidence of increased likelihood of mental health related adverse events.

KW - CPRD

KW - Varenicline

KW - NRT

KW - Smoking Cessation

KW - Neurodevelopmental Disorders

KW - Primary Care

KW - instrumental variable analyses

U2 - 10.1038/s41598-019-54727-5

DO - 10.1038/s41598-019-54727-5

M3 - Article

C2 - 31862899

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 19488

ER -